Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy

Developmental Medicine and Child Neurology

Volumn 55, Issue 11, 2013, Pages 1038-1045

  Mayhew, Anna ^a   Mazzone, Elena S ^b   Eagle, Michelle ^a   Duong, Tina ^c   Ash, Maria ^d   Decostre, Valerie ^e   Vandenhauwe, Marlene ^f   Klingels, Katrijn ^g   Florence, Julaine ^h   Main, Marion ^d   Bianco, Flaviana ^b   Henrikson, Erik ⁱ   Servais, Laurent ^e   Campion, Giles ^j   Vroom, Elizabeth ^k   Ricotti, Valeria ^d   Goemans, Natalie ^f   Mcdonald, Craig ⁱ   Mercuri, Eugenio ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Institut de Myologie   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Prosensa BV   (Netherlands)

^k Duchenne Parent Project   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; DAILY LIFE ACTIVITY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PERFORMANCE OF THE UPPER LIMB MODULE; PRESCHOOL CHILD; PRIORITY JOURNAL; RASCH ANALYSIS; SCHOOL CHILD; SYSTEMATIC REVIEW;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; HUMANS; MOVEMENT DISORDERS; MUSCULAR DYSTROPHY, DUCHENNE; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UPPER EXTREMITY; WALKING;

EID: 84885175848     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12213     Document Type: Article

References (26)

1. Mercuri E, Mayhew A, Muntoni F, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12-13 May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30 June-1 July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11 July 2007, Paris, France. Neuromuscul Disord 2008; 18: 894-903.
2. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010; 42: 966-74.
3. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010; 41: 500-10.
4. Henricson E, Abresch R, Han JJ, et al. Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational influences. PLoS Curr 2012; 4: RRN1297.
5. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010; 20: 712-6.
6. Mazzone E, Vasco G, Sormani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011; 77: 250-6.
7. Mazzone ES, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009; 19: 458-61.
8. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-22.
9. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
10. Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011; 53: 535-42.
11. Scott E, Eagle M, Mayhew A, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012; 17: 101-9.
12. Mazzone ES, Pane M, Sormani MP, et al. 24 month longitudinal data in ambulant boys with duchenne muscular dystrophy. PLoS ONE 2013; 8: e52512.
13. Mercuri E, McDonald C, Mayhew A, et al. International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15-16 February 2012. Neuromuscul Disord 2012; 22: 1025-8.
14. Mazzone E, Vasco G, Palermo C, et al. A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Dev Med Child Neurol 2012; 54: 879-85.
15. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981; 4: 186-97.
16. Zupan A. Assessment of the functional abilities of the upper limbs in patients with neuromuscular diseases. Disabil Rehabil 1996; 18: 69-75.
17. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil 1969; 50: 311-9.
18. Vuillerot C, Girardot F, Payan C, et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol 2010; 52: 60-5.
19. Brooke MH, Fenichel GM, Griggs RC, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989; 39: 475-81.
20. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995; 74: S70-92.
21. McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group Duchenne natural history study - a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 2013; 48: 32-54.
22. Mazzone E, Bianco F, Martinelli D, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 2011; 21: 406-12.
23. Andrich D. Rasch Models for Measurement. Beverly Hills, CA: Sage Publications, 1988.
24. Kurillo G, Han JJ, Abresch RT, Nicorici A, Yan P, Bajcsy R. Development and application of stereo camera-based upper extremity workspace evaluation in patients with neuromuscular diseases. PLoS ONE 2012; 7: e45341.
25. Servais L, Deconinck N, Moraux A, et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord 2012; 23: 139-48.
26. Food and Drug Administration. (2009) Qualification Process for Drug Development Tools [online]. http://www.fda.gov/cber/gdlns/prolbl.pdf, www.fda.gov/cber/gdlns/prolbl.pdf, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. (accessed 31 May 2013).